Enhanced Aerosolization of High Potency Nanoaggregates of Voriconazole by Dry Powder Inhalation

Chaeho Moon, Alan B. Watts, Xingyu Lu, Yongchao Su, Robert O. Williams

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Invasive pulmonary aspergillosis is a deadly fungal infection with a high mortality rate, particularly in patients having undergone transplant surgery. Voriconazole, a triazole antifungal pharmaceutical product, is considered as a first-line therapy for invasive pulmonary aspergillosis, and exhibits efficacy even for patients who have failed other antifungal drug therapies. The objective of this study is to develop high potency nanoaggregates of crystalline voriconazole composition for dry powder inhalation using the particle engineering process, thin film freezing. In this study, mannitol at low concentrations acted as a surface texture-modifying agent, and we evaluated the physicochemical and aerodynamic properties of the voriconazole formulations containing different amounts of mannitol. In vitro aerosol performance data demonstrated that powder formulations consisting of 90 to 97% (w/w) voriconazole were the optimum for inhalation with a fine particle fraction (% of delivered dose) as high as 73.6 ± 3.2% and mass median aerodynamic diameter of 3.03 ± 0.17 μm when delivered by a commercially available device. The thin film freezing process enabled phase-separated submicron crystalline mannitol to be oriented such as to modify the surface texture of the crystalline voriconazole nanoaggregates, thus enhancing their aerosolization. Addition of as low as 3% (w/w) mannitol significantly increased the fine particle fraction (% of metered dose) of voriconazole nanoaggregates when compared to compositions without mannitol (40.8% vs 24.6%, respectively). The aerosol performance of the voriconazole nanoaggregates with 5% (w/w) mannitol was maintained for 13 months at 25 °C/60% RH. Therefore, voriconazole nanoaggregates having low amounts of surface texture-modifying mannitol made by thin film freezing are a feasible local treatment option for invasive pulmonary aspergillosis with high aerosolization efficiency and drug loading for dry powder inhalation. ©

Original languageEnglish (US)
Pages (from-to)1799-1812
Number of pages14
JournalMolecular Pharmaceutics
Volume16
Issue number5
DOIs
StatePublished - May 6 2019

Fingerprint

Powders
Mannitol
Inhalation
Invasive Pulmonary Aspergillosis
Freezing
Aerosols
Triazoles
Voriconazole
Mycoses
Pharmaceutical Preparations
Transplants
Drug Therapy
Equipment and Supplies
Mortality
Therapeutics

Keywords

  • antifungal
  • dry powder inhalation
  • mannitol
  • nanoaggregates
  • surface modification
  • thin film freezing
  • voriconazole

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Enhanced Aerosolization of High Potency Nanoaggregates of Voriconazole by Dry Powder Inhalation. / Moon, Chaeho; Watts, Alan B.; Lu, Xingyu; Su, Yongchao; Williams, Robert O.

In: Molecular Pharmaceutics, Vol. 16, No. 5, 06.05.2019, p. 1799-1812.

Research output: Contribution to journalArticle

Moon, Chaeho ; Watts, Alan B. ; Lu, Xingyu ; Su, Yongchao ; Williams, Robert O. / Enhanced Aerosolization of High Potency Nanoaggregates of Voriconazole by Dry Powder Inhalation. In: Molecular Pharmaceutics. 2019 ; Vol. 16, No. 5. pp. 1799-1812.
@article{63e498515c834f95a932abad89b51cbe,
title = "Enhanced Aerosolization of High Potency Nanoaggregates of Voriconazole by Dry Powder Inhalation",
abstract = "Invasive pulmonary aspergillosis is a deadly fungal infection with a high mortality rate, particularly in patients having undergone transplant surgery. Voriconazole, a triazole antifungal pharmaceutical product, is considered as a first-line therapy for invasive pulmonary aspergillosis, and exhibits efficacy even for patients who have failed other antifungal drug therapies. The objective of this study is to develop high potency nanoaggregates of crystalline voriconazole composition for dry powder inhalation using the particle engineering process, thin film freezing. In this study, mannitol at low concentrations acted as a surface texture-modifying agent, and we evaluated the physicochemical and aerodynamic properties of the voriconazole formulations containing different amounts of mannitol. In vitro aerosol performance data demonstrated that powder formulations consisting of 90 to 97{\%} (w/w) voriconazole were the optimum for inhalation with a fine particle fraction ({\%} of delivered dose) as high as 73.6 ± 3.2{\%} and mass median aerodynamic diameter of 3.03 ± 0.17 μm when delivered by a commercially available device. The thin film freezing process enabled phase-separated submicron crystalline mannitol to be oriented such as to modify the surface texture of the crystalline voriconazole nanoaggregates, thus enhancing their aerosolization. Addition of as low as 3{\%} (w/w) mannitol significantly increased the fine particle fraction ({\%} of metered dose) of voriconazole nanoaggregates when compared to compositions without mannitol (40.8{\%} vs 24.6{\%}, respectively). The aerosol performance of the voriconazole nanoaggregates with 5{\%} (w/w) mannitol was maintained for 13 months at 25 °C/60{\%} RH. Therefore, voriconazole nanoaggregates having low amounts of surface texture-modifying mannitol made by thin film freezing are a feasible local treatment option for invasive pulmonary aspergillosis with high aerosolization efficiency and drug loading for dry powder inhalation. {\circledC}",
keywords = "antifungal, dry powder inhalation, mannitol, nanoaggregates, surface modification, thin film freezing, voriconazole",
author = "Chaeho Moon and Watts, {Alan B.} and Xingyu Lu and Yongchao Su and Williams, {Robert O.}",
year = "2019",
month = "5",
day = "6",
doi = "10.1021/acs.molpharmaceut.8b00907",
language = "English (US)",
volume = "16",
pages = "1799--1812",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Enhanced Aerosolization of High Potency Nanoaggregates of Voriconazole by Dry Powder Inhalation

AU - Moon, Chaeho

AU - Watts, Alan B.

AU - Lu, Xingyu

AU - Su, Yongchao

AU - Williams, Robert O.

PY - 2019/5/6

Y1 - 2019/5/6

N2 - Invasive pulmonary aspergillosis is a deadly fungal infection with a high mortality rate, particularly in patients having undergone transplant surgery. Voriconazole, a triazole antifungal pharmaceutical product, is considered as a first-line therapy for invasive pulmonary aspergillosis, and exhibits efficacy even for patients who have failed other antifungal drug therapies. The objective of this study is to develop high potency nanoaggregates of crystalline voriconazole composition for dry powder inhalation using the particle engineering process, thin film freezing. In this study, mannitol at low concentrations acted as a surface texture-modifying agent, and we evaluated the physicochemical and aerodynamic properties of the voriconazole formulations containing different amounts of mannitol. In vitro aerosol performance data demonstrated that powder formulations consisting of 90 to 97% (w/w) voriconazole were the optimum for inhalation with a fine particle fraction (% of delivered dose) as high as 73.6 ± 3.2% and mass median aerodynamic diameter of 3.03 ± 0.17 μm when delivered by a commercially available device. The thin film freezing process enabled phase-separated submicron crystalline mannitol to be oriented such as to modify the surface texture of the crystalline voriconazole nanoaggregates, thus enhancing their aerosolization. Addition of as low as 3% (w/w) mannitol significantly increased the fine particle fraction (% of metered dose) of voriconazole nanoaggregates when compared to compositions without mannitol (40.8% vs 24.6%, respectively). The aerosol performance of the voriconazole nanoaggregates with 5% (w/w) mannitol was maintained for 13 months at 25 °C/60% RH. Therefore, voriconazole nanoaggregates having low amounts of surface texture-modifying mannitol made by thin film freezing are a feasible local treatment option for invasive pulmonary aspergillosis with high aerosolization efficiency and drug loading for dry powder inhalation. ©

AB - Invasive pulmonary aspergillosis is a deadly fungal infection with a high mortality rate, particularly in patients having undergone transplant surgery. Voriconazole, a triazole antifungal pharmaceutical product, is considered as a first-line therapy for invasive pulmonary aspergillosis, and exhibits efficacy even for patients who have failed other antifungal drug therapies. The objective of this study is to develop high potency nanoaggregates of crystalline voriconazole composition for dry powder inhalation using the particle engineering process, thin film freezing. In this study, mannitol at low concentrations acted as a surface texture-modifying agent, and we evaluated the physicochemical and aerodynamic properties of the voriconazole formulations containing different amounts of mannitol. In vitro aerosol performance data demonstrated that powder formulations consisting of 90 to 97% (w/w) voriconazole were the optimum for inhalation with a fine particle fraction (% of delivered dose) as high as 73.6 ± 3.2% and mass median aerodynamic diameter of 3.03 ± 0.17 μm when delivered by a commercially available device. The thin film freezing process enabled phase-separated submicron crystalline mannitol to be oriented such as to modify the surface texture of the crystalline voriconazole nanoaggregates, thus enhancing their aerosolization. Addition of as low as 3% (w/w) mannitol significantly increased the fine particle fraction (% of metered dose) of voriconazole nanoaggregates when compared to compositions without mannitol (40.8% vs 24.6%, respectively). The aerosol performance of the voriconazole nanoaggregates with 5% (w/w) mannitol was maintained for 13 months at 25 °C/60% RH. Therefore, voriconazole nanoaggregates having low amounts of surface texture-modifying mannitol made by thin film freezing are a feasible local treatment option for invasive pulmonary aspergillosis with high aerosolization efficiency and drug loading for dry powder inhalation. ©

KW - antifungal

KW - dry powder inhalation

KW - mannitol

KW - nanoaggregates

KW - surface modification

KW - thin film freezing

KW - voriconazole

UR - http://www.scopus.com/inward/record.url?scp=85064844897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064844897&partnerID=8YFLogxK

U2 - 10.1021/acs.molpharmaceut.8b00907

DO - 10.1021/acs.molpharmaceut.8b00907

M3 - Article

C2 - 30925839

AN - SCOPUS:85064844897

VL - 16

SP - 1799

EP - 1812

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 5

ER -